Edition:
India

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

267.40CHF
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
CHF267.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
303,505
52-wk High
CHF272.90
52-wk Low
CHF159.23

Select another date:

Thu, Nov 2 2017

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

UPDATE 1-Lonza confirms 2017 outlook, outlines new 2022 targets

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG confirmed its 2017 outlook on Wednesday and outlined new targets through 2022.

Lonza confirms 2017 outlook, outlines new 2022 targets

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG on Wednesday confirmed its 2017 outlook and outlined new targets through to 2022.

BRIEF-Lonza H1 sales 15.1 percent up to CHF 2,323 million

* Lonza delivers strong performance in first half 2017 and sets a strong foundation for continued attractive mid-term growth

Select another date: